Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 40, 3018-3031, August 1, 1980]
© 1980 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ghose, T.
Right arrow Articles by Blair, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ghose, T.
Right arrow Articles by Blair, A. H.

Localization of 131I-labeled Antibodies in Human Renal Cell Carcinomas and in a Mouse Hepatoma and Correlation with Tumor Detection by Photoscanning1

T. Ghose2, S. T. Norvell, J. Aquino, P. Belitsky, J. Tai, A. Guclu and A. H. Blair

Departments of Pathology [T. G., A. G.], Surgery [S. T. N.], Radiology [J. A.], Urology [P. B.], Microbiology [J. T.], and Biochemistry [A. H. B.], Dalhousie University, Halifax, Nova Scotia, Canada B3H 4H7

Xenogeneic anti-human renal cell carcinoma globulins (ARCG's), which had been rendered tumor specific by absorptions with normal human tissues, reacted on immunofluorescence with smears and sections of 21 of 22 human renal cell carcinomas tested, but not with any adult, normal human tissues, including kidney. The i.v. administration of 131I-labeled ARCG followed by photoscanning visualized 13 of 15 primary renal cell carcinomas and metastases in 7 of 8 patients. Immunofluorescence and autoradiography of sections and dissociated cells revealed more ARCG and radioactivity bound to tumor tissue than to adjacent normal tissue. However, assay of tissue digests showed more radioactivity in primary carcinoma than in adjacent renal tissue in five patients, similar amounts in both areas in two patients, and less radioactivity in tumor in another five cases. Correlation of scanning with the extent of tumor localization of 131I showed that all tumors which contained equal or greater radioactivity than did normal kidney, and three of five containing less radioactivity, were successfully imaged.

The s.c. transplants of the mouse H6 hepatoma were visualized by 131I-labeled anti-tumor globulin prepared by a method identical to that for ARCG. If anti-tumor globulin was further purified, a 2-fold increase in the tumor:blood ratio of radioactivity was obtained, but only minor improvement in the quality of scans. 131I-labeled normal rabbit globulin failed to visualize tumors, and 67Ga citrate scanning could not discriminate between hepatoma transplants and Freund's complete adjuvant-induced granulomas.

The tumor specificity of 131I-labeled anti-tumor globulins as imaging agents is supported by: (a) the failure of normal rabbit globulin and 99mTc-sulfur colloid to image the hepatoma and renal carcinoma, respectively; (b) the immunofluorescence and autoradiography evidence that i.v.-administered 131I-ARCG localized in and bound firmly to tumor tissue, but not to adjacent renal tissue; and (c) the fact that the tumor which did not bind 131I-ARCG could not be visualized. It appears that the success of 131I-labeled anti-tumor globulins as imaging agents is associated with their specific tumor localization but can be aided by such nonspecific factors as increased and more permeable tumor vasculature.

1 Presented at the UICC Workshop on Radioimmunodetection of Cancer, July 19 to 21, 1979, Lexington, Ky. This work was supported by grants from the National Cancer Institute of Canada, the Nova Scotia Division of the Canadian Cancer Society, the Medical Research Council, and the Canadian Kidney Foundation.

2 To whom requests for reprints should be addressed.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1980 by the American Association for Cancer Research.